Gliclazide is a second-generation hypoglycaemic sulfonylurea that is useful in the treatment of Type 2 diabetes mellitus. It shows low aqueous solubility and dissolution rate and often shows low and irregular bioavailability after oral administration. This paper describes an approach to improve the Solubility of gliclazide by using solid dispersions (SDs) in polyethylene glycol 4000 (PEG 4000)....

AIM To compare the effects of nateglinide plus metformin with gliclazide plus metformin on glycaemic control in patients with Type 2 diabetes. METHODS Double-blind, double-dummy, parallel group, randomized, multicentre study over 24 weeks. Patients with inadequate glucose control on maximal doses of metformin were randomized to additionally receive nateglinide (n = 133) or gliclazide (n = 129...

Gliclazide is practically insoluble in water and its GI absorption is limited by its dissolution rate. Our previously published works indicated that preparing gliclazide-crosspovidone solid dispersion in the drug/ carrier ratio of 1:1 using cogrinding technique is able to enhance drug dissolution rate. The coground of gliclazide-crosspovidone was administrated to the rats and the hypoglycemic e...

Appropriate experimental models are essential for understanding the underlying mechanisms of diabetes and its complications. Investigations have unsuccessfully tried to recreate in experimental animals the cardiovascular complications of diabetes seen in humans. Sulfonylureas have remained the mainstay of antidiabetic therapy for almost three decades. 1 However the benefits of sulfonylureas bey...

OBJECTIVE AND DESIGN Gliclazide has been associated with a low risk of hypoglycemic episodes and beneficial long-term cardiovascular safety in observational cohorts. The aim of this study was to assess in a systematic review and meta-analysis of randomized controlled trials the safety and efficacy of gliclazide compared to other oral glucose-lowering agents (PROSPERO2013:CRD42013004156). DATA...

We describe a rapid, specific, and precise analysis for gliclazide in plasma by radial compression, reversed-phase, "high-performance" liquid chromatography. Gliclazide and the internal standard, 3-chlorogliclazide, are eluted after 4.4 and 6.8 min, respectively. Only 100 microL of plasma and minimal sample workup are required. The limit of detection for gliclazide in plasma is 0.5 mg/L (1.55 m...

We compared the effects of gliclazide, an antidiabetic agent with antioxidant properties, and N-acetyl-L-cysteine (NAC), a glutathione precursor, in protecting against 2-deoxy-D-ribose- (dRib-) induced oxidative damage in HIT-T15 cells. Using trypan blue staining and flow cytometry with annexin V/PI staining, gliclazide treatment slightly reversed dRib-induced cell death and apoptosis, and NAC ...

Major problem for diabetic patients represents damage of blood vessels and the oxidative stress of the brain cells due to increased concentration of free radicals and poor nutrition of brain cells. Gliclazide has antioxidative properties and poor blood brain barrier (BBB) penetration. Bile acids are known for their hypoglycemic effect and as promoters of drug penetration across biological membr...

Gliclazide is a second generation sulphonylurea oral hypoglycaemic agent used in the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It improves defective insulin secretion and may reverse insulin resistance observed in patients with NIDDM. These actions are reflected in a reduction in blood glucose levels which is maintained during both short and long term administration, and is ...

In this study we tried to determine when in relation to meals gliclazide should be taken for optimum hypoglycemic action. Eight non-insulin-dependent diabetics participated in this study during hospitalization for glycemic control. After stabilization of glycemic control on gliclazide, they took a 40 mg tablet of gliclazide either 30 minutes before, immediately before, or immediately after brea...